These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34783519)

  • 1. Proliferation of Tau 304-380 Fragment Aggregates through Autocatalytic Secondary Nucleation.
    Rodriguez Camargo DC; Sileikis E; Chia S; Axell E; Bernfur K; Cataldi RL; Cohen SIA; Meisl G; Habchi J; Knowles TPJ; Vendruscolo M; Linse S
    ACS Chem Neurosci; 2021 Dec; 12(23):4406-4415. PubMed ID: 34783519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Structure Biology of Tau and Clue for Aggregation Inhibitor Design.
    Wang D; Huang X; Yan L; Zhou L; Yan C; Wu J; Su Z; Huang Y
    Protein J; 2021 Oct; 40(5):656-668. PubMed ID: 34401998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disclosing the Mechanism of Spontaneous Aggregation and Template-Induced Misfolding of the Key Hexapeptide (PHF6) of Tau Protein Based on Molecular Dynamics Simulation.
    Liu H; Zhong H; Liu X; Zhou S; Tan S; Liu H; Yao X
    ACS Chem Neurosci; 2019 Dec; 10(12):4810-4823. PubMed ID: 31661961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligomer Diversity during the Aggregation of the Repeat Region of Tau.
    Kjaergaard M; Dear AJ; Kundel F; Qamar S; Meisl G; Knowles TPJ; Klenerman D
    ACS Chem Neurosci; 2018 Dec; 9(12):3060-3071. PubMed ID: 29953200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resonance Raman spectroscopic measurements delineate the structural changes that occur during tau fibril formation.
    Ramachandran G; Milán-Garcés EA; Udgaonkar JB; Puranik M
    Biochemistry; 2014 Oct; 53(41):6550-65. PubMed ID: 25284680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau as a therapeutic target for Alzheimer's disease.
    Boutajangout A; Sigurdsson EM; Krishnamurthy PK
    Curr Alzheimer Res; 2011 Sep; 8(6):666-77. PubMed ID: 21679154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Melatonin on Tau aggregation and Tau-mediated cell surface morphology.
    Das R; Balmik AA; Chinnathambi S
    Int J Biol Macromol; 2020 Jun; 152():30-39. PubMed ID: 32044365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct observation of secondary nucleation along the fibril surface of the amyloid
    Thacker D; Barghouth M; Bless M; Zhang E; Linse S
    Proc Natl Acad Sci U S A; 2023 Jun; 120(25):e2220664120. PubMed ID: 37307445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granular tau oligomers as intermediates of tau filaments.
    Maeda S; Sahara N; Saito Y; Murayama M; Yoshiike Y; Kim H; Miyasaka T; Murayama S; Ikai A; Takashima A
    Biochemistry; 2007 Mar; 46(12):3856-61. PubMed ID: 17338548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of tau self-aggregation and neurotoxicity.
    Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic studies unravel the complexity inherent in tau aggregation leading to Alzheimer's disease and the tauopathies.
    Ramachandran G; Udgaonkar JB
    Biochemistry; 2013 Jun; 52(24):4107-26. PubMed ID: 23721410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling the Structure and Dynamics of Ac-PHF6-NH
    Stroganova I; Toprakcioglu Z; Willenberg H; Knowles TPJ; Rijs AM
    ACS Chem Neurosci; 2024 Sep; 15(18):3391-3400. PubMed ID: 39215387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalytic Prion-Like Cross-Talk between a Key Alzheimer's Disease Tau-Fragment R3 and the Type 2 Diabetes Peptide IAPP.
    Arya S; Claud SL; Cantrell KL; Bowers MT
    ACS Chem Neurosci; 2019 Nov; 10(11):4757-4765. PubMed ID: 31642657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation and detection of tau aggregation with small-molecule ligands.
    Chang E; Honson NS; Bandyopadhyay B; Funk KE; Jensen JR; Kim S; Naphade S; Kuret J
    Curr Alzheimer Res; 2009 Oct; 6(5):409-14. PubMed ID: 19874263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary nucleation of monomers on fibril surface dominates α-synuclein aggregation and provides autocatalytic amyloid amplification.
    Gaspar R; Meisl G; Buell AK; Young L; Kaminski CF; Knowles TPJ; Sparr E; Linse S
    Q Rev Biophys; 2017 Jan; 50():e6. PubMed ID: 29233218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Neurotoxic Role of Extracellular Tau Protein.
    Sebastián-Serrano Á; de Diego-García L; Díaz-Hernández M
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29584657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of key amino acids responsible for the distinct aggregation properties of microtubule-associated protein 2 and tau.
    Xie C; Soeda Y; Shinzaki Y; In Y; Tomoo K; Ihara Y; Miyasaka T
    J Neurochem; 2015 Oct; 135(1):19-26. PubMed ID: 26134402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau oligomers and aggregation in Alzheimer's disease.
    Meraz-Ríos MA; Lira-De León KI; Campos-Peña V; De Anda-Hernández MA; Mena-López R
    J Neurochem; 2010 Mar; 112(6):1353-67. PubMed ID: 19943854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azure C Targets and Modulates Toxic Tau Oligomers.
    Lo Cascio F; Kayed R
    ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.